Fosaprepitant
- Generic Name
- Fosaprepitant
- Brand Names
- Emend, Focinvez, Ivemend
- Drug Type
- Small Molecule
- Chemical Formula
- C23H22F7N4O6P
- CAS Number
- 172673-20-0
- Unique Ingredient Identifier
- 6L8OF9XRDC
- Background
Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment.
- Indication
Fosaprepitant is indicated in adult and pediatric patients ≥6 months of age, in combination with other antiemetic agents, for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy, including high-dose cisplatin. It is also indicated for the treatment of delayed nausea and v...
- Associated Conditions
- Acute Chemotherapy-Induced Nausea and Vomiting (CINV) caused by highly emetogenic chemotherapy, Delayed Chemotherapy-Induced Nausea and Vomiting (CINV) caused by highly emetogenic chemotherapy, Delayed Chemotherapy-Induced Nausea and Vomiting (CINV) caused by moderately emetogenic chemotherapy
- Associated Therapies
- -
A multicenter, phase II trial of triplet antiemetic therapy with palonosetron, aprepitant, and ...
A phase II trial investigated triplet antiemetic therapy (PALO, APR, OLN) for breast cancer patients undergoing HEC. Conducted from 2019-2022, it involved 8 institutions, enrolling patients aged 20+ with ECOG PS 0–2. Treatment included PALO 0.75 mg, OLN 5 mg for 5 days, and APR 125 mg or fosaprepitant 150 mg. Primary endpoint was TC rate of nausea/vomiting (0–120 h), with secondary endpoints including TC rates in acute/delayed phases, CR of vomiting, CC of nausea/vomiting, and severity of nausea. Statistical analysis aimed to verify TC rate >23% with 80% power, requiring 74 cases, adjusted to 89 considering dropout rate.
Comparative Cost-Effectiveness of Atezolizumab Versus Durvalumab as First-Line
This study assesses the cost-effectiveness of atezolizumab and durvalumab combined with chemotherapy as first-line treatment for extensive-disease small-cell lung cancer (ED-SCLC) in Japan, finding ICERs of 35 and 37 million JPY, respectively, which exceed the 15 million JPY threshold per QALY. Sensitivity analysis suggests significant price reductions are needed for these treatments to be cost-effective, recommending clinical trials to explore smaller dosages and longer intervals to enhance efficiency.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath